Microba Life Sciences Limited

CHIA:MAP Stock Report

Market Cap: AU$80.6m

Microba Life Sciences Future Growth

Future criteria checks 5/6

Microba Life Sciences is forecast to grow earnings and revenue by 45.2% and 39.1% per annum respectively. EPS is expected to grow by 53.4% per annum. Return on equity is forecast to be -9.5% in 3 years.

Key information

45.2%

Earnings growth rate

53.4%

EPS growth rate

Healthcare earnings growth25.1%
Revenue growth rate39.1%
Future return on equity-9.5%
Analyst coverage

Low

Last updated01 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

CHIA:MAP - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2027433N/A12
6/30/202626-19N/A-162
6/30/202520-20N/A-142
6/30/202412-20-20-16N/A
3/31/20249-19-22-18N/A
12/31/20237-18-23-20N/A
9/30/20236-16-19-16N/A
6/30/20235-13-15-12N/A
3/31/20235-12-15-12N/A
12/31/20225-11-14-11N/A
9/30/20225-11-13-11N/A
6/30/20225-11-12-10N/A
3/31/20224-11-11-10N/A
12/31/20214-11-9-9N/A
9/30/20214-9-9-8N/A
6/30/20214-8-8-7N/A
6/30/20203-7-5-4N/A
6/30/20192-5-4-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MAP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: MAP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MAP is expected to become profitable in the next 3 years.

Revenue vs Market: MAP's revenue (39.1% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: MAP's revenue (39.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MAP is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y